SIBO vs. IBS: differences, overlap, and how to tell them apart

If you are looking for the difference between SIBO and IBS, you most likely have bloating, gas, or changes in bowel transit, and at some point you have been given both labels. It is one of the most common sources of confusion in digestive health, and there is a concrete explanation for it: they share almost all of their symptoms, but they are defined in different ways.

The distinction that truly matters is not in the symptoms. It is in how each diagnosis is reached:

• IBS is diagnosed clinically. There is no laboratory test that confirms it. It is diagnosed when the symptoms fit the Rome IV criteria and other relevant causes have been ruled out.
• SIBO is investigated with a test. The hydrogen and methane breath test looks for a pattern of early fermentation consistent with overgrowth.

That is the real dividing line. The rest of this guide develops it with data, shows you the complete Rome IV criteria, and gives you a “if you have X, it makes sense to investigate Y” roadmap.

Author’s note: I’m Beiker, a developer, not a doctor. This site was born when my sister was diagnosed with SIBO and I started researching to support her. What confused me the most was exactly this: depending on who was treating her, the words “SIBO” and “irritable bowel” came up almost as synonyms, and no one explained how they differed or why they coexisted. I spent weeks cross-checking clinical guidelines to understand that they are not the same thing, that they are diagnosed differently, and that having both at once is common. This guide is the summary that would have saved me that confusion.

The differential table that matters

Many SIBO vs. IBS comparisons answer “yes/yes” to almost everything and clarify nothing. The useful difference is not which symptom appears, but how each condition is defined and studied.

	IBS (irritable bowel syndrome)	SIBO (small intestinal bacterial overgrowth)
What it is	A disorder of gut-brain interaction (functional): the gut is structurally healthy but works and hurts in an altered way	An excess or misplacement of bacteria in the small intestine, where normally there are few
How it is diagnosed	Clinically, with the Rome IV criteria + ruling out red flags. There is no confirmatory test	Investigated with a breath test (it is not a clinical diagnosis)
Characteristic test	None confirms it; tests are used to rule out other causes (celiac, IBD)	H₂/CH₄ breath test with lactulose or glucose
What is measured	The pattern of symptoms over time	Gases produced by fermentation: positive if H₂ rises ≥20 ppm over baseline before 90 min, or if methane is ≥10 ppm at any point
Subtype and gas	Classified by stool: IBS-D (diarrhea), IBS-C (constipation), IBS-M (mixed)	Hydrogen is associated more with diarrhea; methane (strictly speaking produced by archaea, called IMO) is associated with constipation
Baseline management	Diet (low-FODMAP), gut-brain axis, motility, drugs by subtype	Reducing the overgrowth and correcting the factor that favors it (motility, anatomy, etc.)

The first two rows are the key: IBS is diagnosed by what you report, SIBO by what a test detects in your breath. That is why the same person can receive both labels, and why no list of symptoms separates them on its own.

The breath test thresholds (≥20 ppm of hydrogen before 90 minutes, ≥10 ppm of methane) come from the North American Consensus on breath testing. The interpretation depends on the substrate used, the preparation, and intestinal transit; a positive result does not automatically explain every symptom. This is detailed in the breath test guide.

The Rome IV criteria for IBS (what a professional actually evaluates)

IBS is not a catch-all bin for “discomfort without a cause”. It has a positive, operational definition. The Rome IV criteria, which the 2021 ACG guideline adopts as its reference, state the following:

Recurrent abdominal pain, on average at least 1 day per week over the last 3 months, associated with 2 or more of these elements:

1. Related to defecation (improves or worsens with bowel movements).
2. Associated with a change in the frequency of stool.
3. Associated with a change in the form or appearance of stool.

The criteria must be met over the last 3 months, with symptom onset at least 6 months before diagnosis.

Three details that are often overlooked:

• Pain is mandatory. Without recurrent abdominal pain, Rome IV is not met, even if there is a lot of bloating or gas. Bloating alone does not equal IBS.
• The link to bowel movements is central. That the pain changes when you go to the bathroom is what distinguishes IBS from other digestive discomfort.
• It is a positive diagnosis, not an endless rule-out. The ACG recommends using a positive diagnostic strategy (confirming that symptoms fit Rome IV) instead of ordering test after test to “rule out everything”. It does so with a strong recommendation and high-quality evidence because of its better cost-effectiveness.

This does not mean “it’s all in your head”. IBS is a real disorder of the communication between gut and brain, with real pain and a real impact on life. It means that it is recognized by its pattern, not by a bacterium or an image.

Which tests make sense (and which do not) according to the ACG

One of the most practical questions is: if I fit IBS, what should they order? The 2021 ACG IBS guideline is fairly concrete, and knowing it helps you arrive better prepared at the appointment:

• Celiac serology in people with IBS and diarrhea: strong recommendation, moderate-quality evidence. Celiac disease mimics IBS-D and is worth ruling out.
• Fecal calprotectin (or lactoferrin) and C-reactive protein when IBS with diarrhea is suspected: strong recommendation, to rule out inflammatory bowel disease.
• Against routine stool testing for enteric pathogens in all patients with IBS: conditional recommendation.
• Against routine colonoscopy in those under 45 years of age without alarm signs: conditional recommendation.

What is striking is what does not appear: the ACG IBS guideline does not recommend routine SIBO breath testing in people with IBS. Not because the overlap does not exist, but because the test has accuracy limitations and a positive result does not automatically change the initial plan. The breath test comes into play in specific contexts (risk factors, lack of response, flags pointing toward overgrowth), not as general screening.

How much they actually overlap

Here is the figure that most pages either hide or exaggerate. The question “what percentage of people with IBS have SIBO?” has an answer with honest nuances.

A systematic review and meta-analysis of 50 studies with 8,398 patients with IBS (Chen et al., Journal of Gastroenterology, 2018) found a pooled prevalence of SIBO of 38% (95% CI: 32-44). People with IBS were almost 5 times more likely to have a positive test than healthy controls (OR 4.7; 95% CI: 3.1-7.2).

But the number depends a great deal on the method:

• With a breath test: ~40% positive.
• With aspirate culture (the stricter method): ~19%.

That difference is the real story of the overlap. The breath test overestimates compared with culture, so any “X% have SIBO” figure should be read with caution: it partly reflects the test that was used, not just the biological reality. The meta-analysis also found that the diarrhea subtype (IBS-D) was more likely to have a positive SIBO test (OR 1.7; 95% CI: 1.3-2.3), which connects with the fact that hydrogen is associated with diarrhea.

A sober conclusion: the overlap is frequent and real, but it is not universal and it does not mean that all IBS “is really SIBO”. It means that, in a significant proportion of people with IBS, there is an overgrowth component that can coexist with —and feed— the symptoms.

Why they coexist

That they overlap so much is no coincidence. They share mechanisms:

• Altered motility. If the migrating motor complex (the “housekeeping” of the gut between meals) fails, bacteria build up. Slow motility is both a feature of IBS-C and fertile ground for SIBO.
• Gut-brain axis and visceral sensitivity. Amplified distension and pain appear in both.
• A previous gastroenteritis. Post-infectious IBS and SIBO share a trigger.

In fact, the ACG guideline itself recommends rifaximin (a locally acting antibiotic) for the global symptoms of IBS with diarrhea —a strong recommendation—. That an antibiotic helps in IBS-D is, in itself, a clue that this subtype has a relevant bacterial component. (This belongs to the realm of treatment; here it only serves as a conceptual bridge, not as a recommendation for use.)

If you have X, it makes sense to investigate Y

A practical way to organize the picture before the appointment:

• You have abdominal pain that improves or worsens with bowel movements, linked to changes in stool, for months, without alarm flags → it fits the Rome IV pattern of IBS. The next step is usually to confirm it clinically and rule out celiac/IBD with tests, not to hunt for a bacterium from the outset.
• You fit IBS-D and do not respond to the initial measures, or you have a history of gastroenteritis → this is a scenario where it makes sense to discuss a breath test or a targeted trial.
• You have marked constipation and pronounced bloating → it is worth considering the methane component (IMO), which is associated with constipation.
• You have risk factors for overgrowth (previous abdominal surgery, diabetes, hypothyroidism, motility disorders, prolonged use of certain medications) → SIBO rises on the list of possibilities and the breath test gains relevance. Review the factors associated with SIBO.
• You have any alarm flag (see below) → no functional label should be assumed before expanding the workup.

The low-FODMAP diet muddies the reading

The low-FODMAP diet works in many people with IBS and reduces the fermentable load that feeds SIBO. That is why it improves symptoms in both conditions, and why improving on low-FODMAP does not prove you had SIBO: it could be IBS, sensitivity to certain carbohydrates, less fermentable volume, or simply fewer ultra-processed foods.

The ACG recommends a limited trial of the low-FODMAP diet in IBS, with the key word being “limited”: it is not meant to be maintained broadly for months. If you tolerate fewer and fewer foods, the priority is to review the case with a professional, not to cut the list further. To understand phases and limits, there is the low-FODMAP diet guide and the recipe-book methodology.

Alarm flags: when no functional label is enough

Both IBS and SIBO are explanations for symptoms in a gut without structural damage. These signs do not fit that framework and require expanding the workup before assuming anything:

• blood in the stool or black stools,
• unintentional weight loss,
• documented anemia or nutritional deficiencies,
• fever, persistent vomiting, or dehydration,
• nighttime diarrhea or pain that wakes you up,
• new symptoms starting at age 45-50,
• a family history of digestive cancer, celiac disease, or IBD.

These signs do not have a single cause, but they justify a broader evaluation. They are detailed in the guide on when to seek care for digestive symptoms.

How to arrive well prepared at the appointment

Bringing your case organized speeds everything up, especially because the ACG favors the positive diagnostic strategy (confirming the pattern instead of ordering endless tests):

• the approximate start date of the symptoms,
• whether the pain improves or worsens with bowel movements (key for Rome IV),
• the relationship with meals, stress, and sleep,
• the stool pattern (frequency and form) and whether diarrhea, constipation, or both predominate,
• results of previous tests, current medications and supplements,
• surgeries, digestive infections, and associated diagnoses.

A diary of 7 to 14 days helps, as long as it does not become a source of anxiety.

In summary

IBS and SIBO resemble each other so closely that they get confused, but they are not the same: IBS is a clinical diagnosis by Rome IV criteria with no confirmatory test, and SIBO is investigated with a breath test. They coexist frequently —around 38% of people with IBS have a positive SIBO test, with a real but method-dependent overlap—, they share mechanisms such as altered motility, and that is why the same person can receive both labels. The prudent way out is not to pick the right side online, but to organize the pattern, recognize the alarm flags, and review it with a health professional.

Disclaimer: this guide is educational and summarizes public sources. It does not diagnose, treat, or replace evaluation by a health professional.

References

1. Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116(1):17-44. PubMed
2. Chen B, Kim JJ, Zhang Y, Du L, Dai N. Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol. 2018;53(7):807-818. PubMed
3. Pimentel M, Saad RJ, Long MD, Rao SSC. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol. 2020;115(2):165-178. PubMed
4. Rezaie A, Buresi M, Lembo A, et al. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. Am J Gastroenterol. 2017;112(5):775-784. PubMed
5. Lacy BE, Mearin F, Chang L, et al. Bowel Disorders (Rome IV criteria). Gastroenterology. 2016;150(6):1393-1407. PubMed